Astec Lifesciences Share Price
541.70+0.00 (-1.95%)
-34.66% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
PIINDNSE
SUMICHEMNSE
BAYERCROPNSE
SHARDACROPNSE
DHANUKANSE
RALLISNSE
NACLINDNSE
BHAGCHEMNSE
GSPCROPNSE
INSECTICIDNSE
ASTECNSE
Astec Lifesciences Share Price
541.70+0.00 (-1.95%)
-34.66% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| 6% | -4% | -11% | 18% |
| - | - | - | 40% |
| 1% | -17% | -24% | -35% |
| 5% | -10% | -27% | -26% |
Peer Comparison
Symbol
PIIND
SUMICHEM
BAYERCROP
SHARDACROP
DHANUKA
RALLIS
NACLIND
BHAGCHEM
GSPCROP
INSECTICID
ASTEC
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,616.4 | ₹24806 Cr | 28.26 | 8.04 | 85.59 | ₹1321 Cr |
| 340.55 | ₹17173 Cr | 30.73 | 3.15 | 12.56 | ₹543 Cr |
| 3,339.4 | ₹15052 Cr | 20.19 | 37.02 | 192.05 | ₹689 Cr |
| 664.6 | ₹6059 Cr | 9.41 | 10.17 | 112.44 | ₹681 Cr |
| 914.85 | ₹4093 Cr | 14.45 | 24.5 | 77.45 | ₹287 Cr |
| 187.9 | ₹3682 Cr | 18.69 | 4.47 | 16.3 | ₹184 Cr |
| 117.5 | ₹2754 Cr | 327.8 | -0.06 | 1.84 | ₹5 Cr |
| 181.1 | ₹2363 Cr | 86.16 | 0.42 | 4.46 | ₹18 Cr |
| 406.4 | ₹1904 Cr | 22.1 | 9.6 | 26.09 | ₹98 Cr |
| 533.1 | ₹1571 Cr | 12.85 | 19.3 | 55.23 | ₹139 Cr |
| 547.7 | ₹1235 Cr | — | -16.79 | -15.41 | -₹81 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 | Sep 2019 | Jun 2019 | Mar 2019 | Dec 2018 | Sep 2018 | Jun 2018 | Mar 2018 | Dec 2017 | Sep 2017 | Jun 2017 | Mar 2017 | Dec 2016 | Sep 2016 | Jun 2016 | Mar 2016 | Dec 2015 | Sep 2015 | Jun 2015 | Mar 2015 | Dec 2014 | Sep 2014 | Jun 2014 | Mar 2014 | Dec 2013 | Sep 2013 | Jun 2013 | Mar 2013 | Dec 2012 | Sep 2012 | Jun 2012 | Mar 2012 | Dec 2011 | Sep 2011 | Jun 2011 | Mar 2011 | Dec 2010 | Sep 2010 | Jun 2010 | Mar 2010 | Dec 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹72 Cr | ₹84 Cr | ₹159 Cr | ₹125 Cr | ₹74 Cr | ₹91 Cr | ₹120 Cr | ₹94 Cr | ₹99 Cr | ₹69 Cr | ₹154 Cr | ₹51 Cr | ₹111 Cr | ₹143 Cr | ₹127 Cr | ₹117 Cr | ₹200 Cr | ₹184 Cr | ₹272 Cr | ₹173 Cr | ₹103 Cr | ₹129 Cr | ₹172 Cr | ₹116 Cr | ₹155 Cr | ₹112 Cr | ₹181 Cr | ₹125 Cr | ₹140 Cr | ₹77 Cr | ₹134 Cr | ₹119 Cr | ₹113 Cr | ₹65 Cr | ₹128 Cr | ₹74 Cr | ₹96 Cr | ₹72 Cr | ₹91 Cr | ₹62 Cr | ₹90 Cr | ₹70 Cr | ₹84 Cr | ₹44 Cr | ₹72 Cr | ₹60 Cr | ₹93 Cr | ₹57 Cr | ₹66 Cr | ₹52 Cr | ₹47 Cr | ₹51 Cr | ₹67 Cr | ₹42 Cr | ₹57 Cr | ₹41 Cr | ₹44 Cr | ₹32 Cr | ₹26 Cr | ₹29 Cr | ₹32 Cr | ₹27 Cr | ₹22 Cr | ₹26 Cr | ₹31 Cr | ₹31 Cr | ₹33 Cr | ₹30 Cr |
| ₹62 L | ₹73 L | ₹3 Cr | ₹82 L | ₹1 Cr | ₹51 L | ₹79 L | ₹2 Cr | ₹2 Cr | ₹92 L | ₹2 Cr | ₹91 L | ₹98 L | ₹2 Cr | ₹3 Cr | ₹4 Cr | ₹4 Cr | ₹3 Cr | ₹7 Cr | ₹2 Cr | ₹90 L | ₹80 L | ₹2 Cr | ₹3 Cr | ₹2 Cr | ₹1 Cr | ₹5 Cr | ₹4 Cr | ₹2 Cr | ₹94 L | ₹6 Cr | ₹3 Cr | ₹2 Cr | ₹47 L | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹3 Cr | ₹92 L | ₹1 Cr | ₹34 L | ₹36 L | ₹5 Cr | ₹0 | ₹0 | ₹37 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹21 L | ₹0 | ₹0 | ₹17 L | ₹54 L | ₹28 L | ₹3 Cr | ₹47 L | ₹7 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹16 L | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹73 Cr | ₹84 Cr | ₹161 Cr | ₹126 Cr | ₹75 Cr | ₹92 Cr | ₹120 Cr | ₹96 Cr | ₹101 Cr | ₹70 Cr | ₹156 Cr | ₹52 Cr | ₹112 Cr | ₹145 Cr | ₹130 Cr | ₹121 Cr | ₹204 Cr | ₹187 Cr | ₹279 Cr | ₹175 Cr | ₹103 Cr | ₹129 Cr | ₹173 Cr | ₹119 Cr | ₹157 Cr | ₹113 Cr | ₹186 Cr | ₹129 Cr | ₹142 Cr | ₹78 Cr | ₹140 Cr | ₹122 Cr | ₹115 Cr | ₹65 Cr | ₹130 Cr | ₹76 Cr | ₹98 Cr | ₹75 Cr | ₹91 Cr | ₹64 Cr | ₹91 Cr | ₹71 Cr | ₹89 Cr | ₹44 Cr | ₹72 Cr | ₹60 Cr | ₹93 Cr | ₹57 Cr | ₹66 Cr | ₹52 Cr | ₹47 Cr | ₹51 Cr | ₹67 Cr | ₹43 Cr | ₹58 Cr | ₹41 Cr | ₹47 Cr | ₹33 Cr | ₹26 Cr | ₹29 Cr | ₹32 Cr | ₹27 Cr | ₹22 Cr | ₹27 Cr | ₹31 Cr | ₹31 Cr | ₹33 Cr | ₹30 Cr |
| ₹103 Cr | ₹95 Cr | ₹161 Cr | ₹132 Cr | ₹91 Cr | ₹114 Cr | ₹126 Cr | ₹111 Cr | ₹130 Cr | ₹125 Cr | ₹150 Cr | ₹78 Cr | ₹123 Cr | ₹149 Cr | ₹129 Cr | ₹114 Cr | ₹175 Cr | ₹168 Cr | ₹217 Cr | ₹140 Cr | ₹90 Cr | ₹110 Cr | ₹140 Cr | ₹107 Cr | ₹132 Cr | ₹90 Cr | ₹144 Cr | ₹110 Cr | ₹131 Cr | ₹76 Cr | ₹116 Cr | ₹104 Cr | ₹94 Cr | ₹60 Cr | ₹101 Cr | ₹65 Cr | ₹85 Cr | ₹66 Cr | ₹79 Cr | ₹53 Cr | ₹71 Cr | ₹62 Cr | ₹72 Cr | ₹60 Cr | ₹63 Cr | ₹49 Cr | ₹75 Cr | ₹49 Cr | ₹54 Cr | ₹47 Cr | ₹42 Cr | ₹46 Cr | ₹60 Cr | ₹38 Cr | ₹52 Cr | ₹38 Cr | ₹41 Cr | ₹30 Cr | ₹25 Cr | ₹28 Cr | ₹30 Cr | ₹23 Cr | ₹23 Cr | ₹24 Cr | ₹27 Cr | ₹26 Cr | ₹28 Cr | ₹23 Cr |
| -₹19 Cr | ₹6 L | ₹12 Cr | ₹5 Cr | -₹6 Cr | -₹10 Cr | ₹6 Cr | -₹4 Cr | -₹18 Cr | -₹45 Cr | ₹15 Cr | -₹17 Cr | -₹2 Cr | ₹5 Cr | ₹8 Cr | ₹16 Cr | ₹37 Cr | ₹28 Cr | ₹72 Cr | ₹45 Cr | ₹22 Cr | ₹25 Cr | ₹40 Cr | ₹19 Cr | ₹31 Cr | ₹30 Cr | ₹48 Cr | ₹25 Cr | ₹17 Cr | ₹7 Cr | ₹29 Cr | ₹24 Cr | ₹25 Cr | ₹9 Cr | ₹33 Cr | ₹15 Cr | ₹16 Cr | ₹12 Cr | ₹17 Cr | ₹13 Cr | ₹24 Cr | ₹12 Cr | ₹20 Cr | -₹12 Cr | ₹13 Cr | ₹14 Cr | ₹19 Cr | ₹12 Cr | ₹15 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹11 Cr | ₹8 Cr | ₹9 Cr | ₹6 Cr | ₹9 Cr | ₹5 Cr | ₹3 Cr | ₹4 Cr | ₹4 Cr | ₹5 Cr | ₹1 Cr | ₹4 Cr | ₹5 Cr | ₹6 Cr | ₹6 Cr | ₹7 Cr |
| ₹7 Cr | ₹8 Cr | ₹8 Cr | ₹7 Cr | ₹8 Cr | ₹11 Cr | ₹10 Cr | ₹10 Cr | ₹9 Cr | ₹7 Cr | ₹7 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹5 Cr | ₹4 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹3 Cr | ₹4 Cr | ₹3 Cr | ₹3 Cr | ₹4 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹4 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹93 L | ₹1 Cr | ₹92 L | ₹55 L | ₹1 Cr |
| -₹37 Cr | -₹19 Cr | -₹8 Cr | -₹16 Cr | -₹24 Cr | -₹33 Cr | -₹16 Cr | -₹25 Cr | -₹39 Cr | -₹62 Cr | -₹93 L | -₹32 Cr | -₹18 Cr | -₹11 Cr | -₹6 Cr | ₹1 Cr | ₹25 Cr | ₹15 Cr | ₹58 Cr | ₹33 Cr | ₹12 Cr | ₹17 Cr | ₹32 Cr | ₹11 Cr | ₹24 Cr | ₹22 Cr | ₹40 Cr | ₹16 Cr | ₹8 Cr | -₹2 Cr | ₹20 Cr | ₹15 Cr | ₹18 Cr | ₹2 Cr | ₹27 Cr | ₹13 Cr | ₹10 Cr | ₹6 Cr | ₹4 Cr | ₹4 Cr | ₹15 Cr | ₹5 Cr | ₹15 Cr | -₹23 Cr | -₹3 Cr | ₹7 Cr | -₹2 Cr | ₹5 Cr | ₹8 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr | ₹4 Cr | ₹2 Cr | ₹4 Cr | ₹37 L | ₹4 Cr | ₹81 L | -₹1 Cr | ₹16 L | ₹31 L | ₹2 Cr | -₹2 Cr | ₹2 Cr | ₹3 Cr | ₹4 Cr | ₹4 Cr | ₹5 Cr |
| -₹37 Cr | -₹19 Cr | -₹8 Cr | -₹16 Cr | -₹24 Cr | -₹33 Cr | -₹16 Cr | -₹40 Cr | -₹39 Cr | -₹40 Cr | -₹96 L | -₹24 Cr | -₹13 Cr | -₹8 Cr | -₹5 Cr | ₹85 L | ₹18 Cr | ₹11 Cr | ₹43 Cr | ₹25 Cr | ₹9 Cr | ₹13 Cr | ₹24 Cr | ₹7 Cr | ₹18 Cr | ₹16 Cr | ₹31 Cr | ₹12 Cr | ₹5 Cr | -₹1 Cr | ₹13 Cr | ₹10 Cr | ₹12 Cr | ₹1 Cr | ₹17 Cr | ₹7 Cr | ₹7 Cr | ₹4 Cr | ₹3 Cr | ₹71 L | ₹11 Cr | ₹4 Cr | ₹6 Cr | -₹17 Cr | -₹1 Cr | ₹5 Cr | ₹3 Cr | ₹4 Cr | ₹6 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹3 Cr | ₹1 Cr | ₹3 Cr | ₹3 L | ₹3 Cr | ₹19 L | -₹87 L | ₹3 L | ₹28 L | ₹2 Cr | -₹2 Cr | ₹2 Cr | ₹2 Cr | ₹3 Cr | ₹3 Cr | ₹4 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Miscellaneous Expenses not written off
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | Mar 2009 | Mar 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹22 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹19 Cr | ₹19 Cr | ₹19 Cr | ₹18 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹9 Cr | ₹9 Cr |
| ₹12 L | ₹11 L | ₹38 L | ₹36 L | ₹29 L | ₹42 L | ₹67 L | ₹77 L | ₹89 L | ₹73 L | ₹75 L | ₹0 | ₹0 | ₹41 L | ₹1 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹368 Cr | ₹215 Cr | ₹349 Cr | ₹399 Cr | ₹377 Cr | ₹289 Cr | ₹226 Cr | ₹182 Cr | ₹149 Cr | ₹118 Cr | ₹98 Cr | ₹116 Cr | ₹95 Cr | ₹87 Cr | ₹80 Cr | ₹80 Cr | ₹76 Cr | ₹23 Cr | ₹13 Cr |
| ₹368 Cr | ₹215 Cr | ₹349 Cr | ₹399 Cr | ₹377 Cr | ₹289 Cr | ₹226 Cr | ₹182 Cr | ₹149 Cr | ₹118 Cr | ₹98 Cr | ₹116 Cr | ₹95 Cr | ₹87 Cr | ₹80 Cr | ₹80 Cr | ₹76 Cr | ₹23 Cr | ₹13 Cr |
| ₹391 Cr | ₹235 Cr | ₹369 Cr | ₹419 Cr | ₹396 Cr | ₹309 Cr | ₹247 Cr | ₹202 Cr | ₹170 Cr | ₹138 Cr | ₹118 Cr | ₹135 Cr | ₹113 Cr | ₹106 Cr | ₹99 Cr | ₹97 Cr | ₹93 Cr | ₹32 Cr | ₹23 Cr |
| ₹31 L | ₹27 L | ₹23 L | ₹19 L | ₹16 L | ₹14 L | ₹33 L | ₹31 L | ₹28 L | ₹15 L | ₹9 L | ₹5 L | ₹4 L | ₹13 L | ₹18 L | ₹23 L | ₹23 L | ₹23 L | ₹22 L |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹25 L | ₹40 L | ₹8 Cr | ₹13 Cr | ₹18 Cr | ₹21 Cr | ₹11 Cr | ₹41 Cr | ₹34 Cr | ₹41 Cr | ₹32 Cr |
| ₹50 Cr | ₹280 Cr | ₹199 Cr | ₹11 Cr | ₹0 | ₹40 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹50 L | ₹50 L | ₹0 | ₹71 L | ₹2 Cr | ₹3 Cr | ₹3 Cr | ₹98 L |
| ₹4 L | ₹4 L | ₹7 Cr | ₹21 Cr | ₹8 Cr | ₹5 Cr | ₹6 Cr | ₹9 Cr | ₹4 Cr | ₹1 Cr | -₹2 Cr | ₹5 Cr | ₹4 Cr | ₹4 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr |
| ₹0 | ₹29 L | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹30 Cr | ₹31 Cr | ₹26 Cr | ₹22 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹1 Cr | ₹6 Cr | ₹48 L | ₹50 L | ₹29 Cr | ₹52 L | ₹32 L | ₹23 L | ₹17 L | ₹7 L | ₹45 L | ₹74 L | ₹73 L | ₹1 Cr | ₹34 L | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹51 Cr | ₹286 Cr | ₹208 Cr | ₹34 Cr | ₹38 Cr | ₹46 Cr | ₹6 Cr | ₹9 Cr | ₹5 Cr | ₹2 Cr | ₹6 Cr | ₹49 Cr | ₹54 Cr | ₹53 Cr | ₹36 Cr | ₹46 Cr | ₹38 Cr | ₹45 Cr | ₹34 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹88 Cr | ₹82 Cr | ₹89 Cr | ₹177 Cr | ₹190 Cr | ₹128 Cr | ₹202 Cr | ₹63 Cr | ₹100 Cr | ₹57 Cr | ₹68 Cr | ₹88 Cr | ₹46 Cr | ₹46 Cr | ₹31 Cr | ₹23 Cr | ₹15 Cr | ₹15 Cr | ₹0 |
| ₹100 Cr | ₹19 Cr | ₹24 Cr | ₹63 Cr | ₹61 Cr | ₹46 Cr | ₹17 Cr | ₹10 Cr | ₹14 Cr | ₹10 Cr | ₹25 Cr | ₹8 Cr | ₹10 Cr | ₹6 Cr | ₹5 Cr | ₹6 Cr | ₹89 L | ₹68 L | ₹21 Cr |
| ₹310 Cr | ₹264 Cr | ₹283 Cr | ₹285 Cr | ₹239 Cr | ₹147 Cr | ₹99 Cr | ₹176 Cr | ₹124 Cr | ₹126 Cr | ₹109 Cr | ₹77 Cr | ₹57 Cr | ₹47 Cr | ₹59 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹2 Cr | ₹98 L | ₹1 Cr | ₹75 L | ₹43 L | ₹63 L | ₹54 L | ₹36 L | ₹44 L | ₹50 L | ₹1 Cr | ₹5 Cr | ₹4 Cr | ₹3 Cr | ₹1 Cr | ₹7 Cr | ₹7 Cr | ₹4 Cr | ₹0 |
| ₹500 Cr | ₹366 Cr | ₹397 Cr | ₹526 Cr | ₹491 Cr | ₹322 Cr | ₹318 Cr | ₹249 Cr | ₹238 Cr | ₹194 Cr | ₹203 Cr | ₹178 Cr | ₹117 Cr | ₹102 Cr | ₹96 Cr | ₹36 Cr | ₹22 Cr | ₹20 Cr | ₹21 Cr |
| ₹942 Cr | ₹887 Cr | ₹975 Cr | ₹979 Cr | ₹925 Cr | ₹678 Cr | ₹572 Cr | ₹461 Cr | ₹413 Cr | ₹334 Cr | ₹328 Cr | ₹362 Cr | ₹284 Cr | ₹261 Cr | ₹231 Cr | ₹179 Cr | ₹154 Cr | ₹98 Cr | ₹79 Cr |
| ₹184 Cr | ₹157 Cr | ₹212 Cr | ₹203 Cr | ₹244 Cr | ₹212 Cr | ₹230 Cr | ₹185 Cr | ₹177 Cr | ₹182 Cr | ₹194 Cr | ₹170 Cr | ₹28 Cr | ₹26 Cr | ₹19 Cr | ₹22 Cr | ₹16 Cr | ₹9 Cr | ₹0 |
| ₹449 Cr | ₹555 Cr | ₹494 Cr | ₹341 Cr | ₹279 Cr | ₹187 Cr | ₹99 Cr | ₹176 Cr | ₹125 Cr | ₹127 Cr | ₹127 Cr | ₹93 Cr | ₹83 Cr | ₹73 Cr | ₹74 Cr | ₹44 Cr | ₹37 Cr | ₹44 Cr | ₹33 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹754 Cr | ₹749 Cr | ₹592 Cr | ₹488 Cr | ₹477 Cr | ₹316 Cr | ₹271 Cr | ₹221 Cr | ₹150 Cr | ₹124 Cr | ₹105 Cr | ₹201 Cr | ₹188 Cr | ₹161 Cr | ₹105 Cr | ₹92 Cr | ₹58 Cr | ₹43 Cr | ₹40 Cr |
| ₹295 Cr | ₹250 Cr | ₹206 Cr | ₹170 Cr | ₹137 Cr | ₹103 Cr | ₹77 Cr | ₹54 Cr | ₹35 Cr | ₹22 Cr | ₹10 Cr | ₹68 Cr | ₹55 Cr | ₹40 Cr | ₹29 Cr | ₹20 Cr | ₹14 Cr | ₹10 Cr | ₹7 Cr |
| ₹459 Cr | ₹499 Cr | ₹386 Cr | ₹318 Cr | ₹340 Cr | ₹213 Cr | ₹194 Cr | ₹167 Cr | ₹115 Cr | ₹103 Cr | ₹95 Cr | ₹133 Cr | ₹132 Cr | ₹121 Cr | ₹76 Cr | ₹73 Cr | ₹44 Cr | ₹33 Cr | ₹34 Cr |
| ₹20 L | ₹13 L | ₹148 Cr | ₹112 Cr | ₹14 Cr | ₹112 Cr | ₹22 Cr | ₹19 Cr | ₹42 Cr | ₹8 Cr | ₹18 Cr | ₹11 Cr | ₹6 Cr | ₹13 Cr | ₹44 Cr | ₹9 Cr | ₹8 Cr | ₹0 | ₹0 |
| ₹53,000 | ₹53,000 | ₹53,000 | ₹53,000 | ₹53,000 | ₹53,000 | ₹53,000 | ₹53,000 | ₹53,000 | ₹53,000 | ₹53,000 | ₹2 L | ₹1 L | ₹8 L | ₹1 L | ₹8 Cr | ₹26 Cr | ₹12 L | ₹0 |
| ₹53,000 | ₹53,000 | ₹53,000 | ₹53,000 | ₹53,000 | ₹53,000 | ₹53,000 | ₹53,000 | ₹53,000 | ₹53,000 | ₹53,000 | ₹2 L | ₹1 L | ₹8 L | ₹1 L | ₹8 Cr | ₹26 Cr | ₹12 L | ₹0 |
| ₹21 Cr | ₹26 Cr | ₹25 Cr | ₹36 Cr | ₹47 Cr | ₹19 Cr | ₹22 Cr | ₹27 Cr | ₹25 Cr | ₹22 Cr | ₹18 Cr | ₹13 Cr | ₹11 Cr | ₹9 Cr | ₹3 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹3 Cr | ₹4 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹499 Cr | ₹546 Cr | ₹576 Cr | ₹481 Cr | ₹410 Cr | ₹347 Cr | ₹240 Cr | ₹213 Cr | ₹182 Cr | ₹135 Cr | ₹136 Cr | ₹158 Cr | ₹150 Cr | ₹143 Cr | ₹123 Cr | ₹90 Cr | ₹77 Cr | ₹33 Cr | ₹34 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹9 L | ₹5 L | ₹2 L | ₹12 Cr | ₹0 | ₹0 | ₹0 | ₹12 L |
| ₹138 Cr | ₹160 Cr | ₹196 Cr | ₹295 Cr | ₹187 Cr | ₹106 Cr | ₹121 Cr | ₹93 Cr | ₹78 Cr | ₹66 Cr | ₹71 Cr | ₹72 Cr | ₹77 Cr | ₹51 Cr | ₹50 Cr | ₹37 Cr | ₹33 Cr | ₹29 Cr | ₹19 Cr |
| ₹248 Cr | ₹147 Cr | ₹169 Cr | ₹155 Cr | ₹274 Cr | ₹187 Cr | ₹161 Cr | ₹122 Cr | ₹123 Cr | ₹111 Cr | ₹81 Cr | ₹104 Cr | ₹51 Cr | ₹63 Cr | ₹32 Cr | ₹34 Cr | ₹32 Cr | ₹29 Cr | ₹18 Cr |
| ₹12 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹4 Cr | ₹6 Cr | ₹12 Cr | ₹4 Cr | ₹5 Cr | ₹4 Cr | ₹3 Cr | ₹2 Cr | ₹1 Cr | ₹2 Cr |
| ₹4 Cr | ₹5 Cr | ₹7 Cr | ₹5 Cr | ₹10 Cr | ₹4 Cr | ₹6 Cr | ₹2 Cr | ₹1 Cr | ₹61 L | ₹2 Cr | ₹54 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹41 Cr | ₹26 Cr | ₹24 Cr | ₹42 Cr | ₹43 Cr | ₹31 Cr | ₹42 Cr | ₹30 Cr | ₹27 Cr | ₹17 Cr | ₹31 Cr | ₹15 Cr | ₹2 Cr | ₹9 L | ₹10 Cr | ₹15 Cr | ₹9 Cr | ₹4 Cr | ₹6 Cr |
| ₹443 Cr | ₹341 Cr | ₹398 Cr | ₹499 Cr | ₹516 Cr | ₹330 Cr | ₹332 Cr | ₹248 Cr | ₹232 Cr | ₹198 Cr | ₹191 Cr | ₹204 Cr | ₹135 Cr | ₹119 Cr | ₹108 Cr | ₹90 Cr | ₹76 Cr | ₹63 Cr | ₹44 Cr |
| -₹57 Cr | -₹25 Cr | ₹1 Cr | -₹27 Cr | ₹25 Cr | ₹8 Cr | ₹13 Cr | -₹33 L | -₹7 Cr | ₹5 Cr | -₹12 Cr | ₹26 Cr | ₹18 Cr | ₹16 Cr | ₹12 Cr | ₹53 Cr | ₹54 Cr | ₹44 Cr | ₹23 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹5 L | ₹18 L | ₹1 Cr | ₹87 L |
| ₹942 Cr | ₹887 Cr | ₹975 Cr | ₹979 Cr | ₹925 Cr | ₹678 Cr | ₹572 Cr | ₹461 Cr | ₹413 Cr | ₹334 Cr | ₹328 Cr | ₹362 Cr | ₹284 Cr | ₹261 Cr | ₹231 Cr | ₹179 Cr | ₹154 Cr | ₹98 Cr | ₹79 Cr |
| ₹175 | ₹120 | ₹188 | ₹214 | ₹202 | ₹158 | ₹126 | ₹103 | ₹86 | ₹70 | ₹60 | ₹70 | ₹61 | ₹58 | ₹57 | ₹57 | ₹55 | ₹33 | ₹23 |
| ₹175 | ₹119 | ₹187 | ₹214 | ₹202 | ₹158 | ₹126 | ₹103 | ₹86 | ₹70 | ₹60 | ₹70 | ₹61 | ₹58 | ₹57 | ₹57 | ₹55 | ₹33 | ₹23 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent of Subsidiaries under liquidations
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | Mar 2009 | Mar 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -₹81 Cr | -₹141 Cr | -₹62 Cr | ₹35 Cr | ₹121 Cr | ₹89 Cr | ₹61 Cr | ₹56 Cr | ₹56 Cr | ₹29 Cr | ₹12 Cr | ₹19 Cr | ₹11 Cr | ₹9 Cr | ₹2 Cr | ₹7 Cr | ₹17 Cr | ₹12 Cr | ₹0 |
| ₹79 Cr | ₹101 Cr | ₹63 Cr | ₹51 Cr | ₹44 Cr | ₹29 Cr | ₹37 Cr | ₹30 Cr | ₹18 Cr | ₹35 Cr | ₹19 Cr | ₹23 Cr | ₹22 Cr | ₹17 Cr | ₹14 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹0 |
| -₹78 Cr | ₹27 Cr | ₹10 Cr | -₹6 Cr | -₹112 Cr | -₹103 Cr | ₹88 Cr | -₹55 Cr | ₹6 Cr | -₹38 Cr | -₹39 Cr | -₹32 Cr | -₹17 Cr | -₹8 Cr | -₹6 Cr | ₹4 Cr | -₹11 Cr | -₹22 Cr | ₹0 |
| -₹80 Cr | -₹13 Cr | ₹12 Cr | ₹80 Cr | ₹53 Cr | ₹15 Cr | ₹187 Cr | ₹32 Cr | ₹80 Cr | ₹26 Cr | -₹8 Cr | ₹10 Cr | ₹16 Cr | ₹18 Cr | ₹10 Cr | ₹19 Cr | ₹14 Cr | -₹82 L | ₹0 |
| -₹81 Cr | -₹8 Cr | ₹10 Cr | ₹75 Cr | ₹24 Cr | -₹8 Cr | ₹168 Cr | ₹15 Cr | ₹65 Cr | ₹19 Cr | -₹13 Cr | ₹7 Cr | ₹15 Cr | ₹16 Cr | ₹9 Cr | ₹16 Cr | ₹10 Cr | -₹2 Cr | ₹0 |
| -₹4 Cr | -₹15 Cr | -₹135 Cr | -₹113 Cr | -₹104 Cr | -₹73 Cr | -₹74 Cr | -₹52 Cr | -₹49 Cr | -₹18 Cr | -₹16 Cr | -₹19 Cr | -₹19 Cr | -₹13 Cr | -₹50 Cr | -₹17 Cr | -₹59 Cr | -₹3 Cr | ₹0 |
| ₹94 Cr | ₹24 Cr | ₹125 Cr | ₹38 Cr | ₹80 Cr | ₹81 Cr | -₹95 Cr | ₹37 Cr | -₹18 Cr | -₹94 L | ₹31 Cr | ₹12 Cr | ₹3 Cr | -₹2 Cr | ₹42 Cr | ₹2 Cr | ₹49 Cr | ₹5 Cr | ₹0 |
| ₹9 Cr | ₹10 L | -₹19,000 | -₹8 L | ₹22 L | ₹6 L | ₹10 L | -₹12 L | -₹3 Cr | ₹60 L | ₹2 Cr | -₹8 L | -₹67 L | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹76 L | -₹48 L | ₹0 |
| ₹58 L | ₹47 L | ₹47 L | ₹55 L | ₹34 L | ₹31 L | ₹21 L | ₹33 L | ₹3 Cr | ₹2 Cr | ₹68 L | ₹78 L | ₹5 Cr | ₹4 Cr | ₹3 Cr | ₹2 Cr | ₹1 Cr | ₹2 Cr | ₹0 |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹3 L | ₹0 | ₹0 | ₹0 | ₹0 | -₹52 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹10 Cr | ₹58 L | ₹47 L | ₹47 L | ₹55 L | ₹34 L | ₹31 L | ₹21 L | ₹33 L | ₹3 Cr | ₹2 Cr | ₹70 L | ₹4 Cr | ₹5 Cr | ₹4 Cr | ₹3 Cr | ₹2 Cr | ₹1 Cr | ₹0 |
Fundamental Ratios
Consolidated
Standalone

No results found
Astec Lifesciences Share Price
541.70+0.00 (-1.95%)
-34.66% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 0
Bearish signals: 6 out of 9 oscillators
RSI
35.18Sell
STOCH %K
45.60Neutral
MACD Level(12,26)
-30.29Sell
Ultimate Oscillator
47.69Sell
Aroon Oscillator
-68.00Sell
BOP
-0.54Sell
CCI
-62.84Neutral
Williams %R
-54.40Neutral
Momentum
-6.85Sell
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 0
Bearish signals: 9 out of 9 moving averages
EMA 9
551.28Sell
SMA 9
544.76Sell
EMA 21
576.46Sell
SMA 21
569.18Sell
EMA 50
616.97Sell
SMA 50
655.62Sell
EMA 200
668.22Sell
SMA 200
659.72Sell
WMA 20
552.37Sell
Pivot
Pivot
Classic
Resistance 5
616.25
Resistance 4
599.85
Resistance 3
583.45
Resistance 2
567.05
Resistance 1
559.75
Pivot
550.65
Support 1
543.35
Support 2
534.25
Support 3
517.85
Support 4
501.45
Support 5
485.05
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Astec Lifesciences Share Price
541.70+0.00 (-1.95%)
-34.66% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| 71.96% | 71.96% | 71.97% | 71.97% | 72.42% | 70.87% |
| 0.02% | 0.01% | 0.03% | 0.04% | 0.00% | 0.02% |
| 0.32% | 0.31% | 0.31% | 0.15% | 0.00% | 0.28% |
| 3.02% | 3.02% | 3.02% | 3.02% | 4.01% | 3.98% |
| 24.68% | 24.70% | 24.67% | 24.82% | 23.57% | 24.85% |
Bulk & block deals
Name
Nk Securities Research Private Limited
Microcurves Trading Private Limited
Qe Securities Llp
Qe Securities Llp
Alphagrep Securities Private Limited
Junomoneta Finsol Private Limited
Junomoneta Finsol Private Limited
Microcurves Trading Private Limited
Alphagrep Securities Private Limited
Nk Securities Research Private Limited
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 09 Sep 2026 | Purchase | 13.01 Cr | ₹752.39 | 1.73 L | Bulk | 0.776186 | NSE |
| 09 Sep 2026 | Sell | 19.27 Cr | ₹753.10 | 2.56 L | Bulk | 1.148559 | NSE |
| 09 Sep 2026 | Sell | 13.56 Cr | ₹750.44 | 1.81 L | Bulk | 0.811092 | NSE |
| 09 Sep 2026 | Purchase | 13.59 Cr | ₹754.57 | 1.80 L | Bulk | 0.808283 | NSE |
| 09 Sep 2026 | Sell | 14.29 Cr | ₹749.68 | 1.91 L | Bulk | 0.855305 | NSE |
| 09 Sep 2026 | Sell | 14.84 Cr | ₹754.71 | 1.97 L | Bulk | 0.882299 | NSE |
| 09 Sep 2026 | Purchase | 14.63 Cr | ₹754.50 | 1.94 L | Bulk | 0.870384 | NSE |
| 09 Sep 2026 | Purchase | 19.26 Cr | ₹752.60 | 2.56 L | Bulk | 1.148559 | NSE |
| 09 Sep 2026 | Purchase | 14.28 Cr | ₹749.27 | 1.91 L | Bulk | 0.855305 | NSE |
| 09 Sep 2026 | Sell | 13.02 Cr | ₹752.70 | 1.73 L | Bulk | 0.776186 | NSE |
Insider trading & SAST
Client name
Godrej Agrovet Ltd
Godrej Agrovet Limited
Nadir Godrej & Others
Nisaba Godrej
Pirojsha Godrej
Tanya Dubash
Nadir Godrej
Ashok V. Hiremath
Dr. P.l. Tiwari
Suresh Hiremath
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 01 Aug 2025 | Promoter | Acquisition | 3.67 | 67.03 | 0 | — | 25.31 L | 29 Jul 2025 | Market | 1,49,35,245 | SAST | 29(2) | — |
| 31 Jul 2025 | Promoter | Acquisition | 9.977027 | 67.03 | 199.02 Cr | ₹890 | 22.36 L | 29 Jul 2025 | Allotment | 1,49,35,245 | Insider Trading | — | Equity Shares |
| 15 Jan 2025 | Promoter | Acquisition | 4.13 | 4.13 | 0 | — | 8.10 L | 01 Jan 2025 | Market | 8,09,563 | SAST | 29(2) | — |
| 02 Jan 2025 | Promoter Group | Acquisition | 0.688141 | 0.69 | 14.78 Cr | ₹1,094.96 | 1.35 L | 01 Jan 2025 | Others | 1,34,954 | Insider Trading | — | Equity Shares |
| 02 Jan 2025 | Promoter Group | Acquisition | 0.687728 | 0.69 | 14.77 Cr | ₹1,094.96 | 1.35 L | 01 Jan 2025 | Others | 1,34,873 | Insider Trading | — | Equity Shares |
| 02 Jan 2025 | Promoter Group | Acquisition | 0.688141 | 0.69 | 14.78 Cr | ₹1,094.96 | 1.35 L | 01 Jan 2025 | Others | 1,34,954 | Insider Trading | — | Equity Shares |
| 02 Jan 2025 | Promoter Group | Acquisition | 2.064014 | 2.06 | 44.32 Cr | ₹1,094.96 | 4.05 L | 01 Jan 2025 | Others | 4,04,782 | Insider Trading | — | Equity Shares |
| 24 Dec 2024 | Promoter | Pledge | — | — | 0 | — | 16.63 L | 02 Dec 2015 | Release | 0 | SAST | Reg31 | — |
| 24 Dec 2024 | Promoter | Pledge | — | — | 0 | — | 2.40 L | 14 Aug 2015 | Release | 0 | SAST | Reg31 | — |
| 24 Dec 2024 | Promoter | Pledge | — | — | 0 | — | 2.09 L | 14 Aug 2015 | Release | 0 | SAST | Reg31 | — |
Astec Lifesciences Share Price
541.70+0.00 (-1.95%)
-34.66% past 1 Year
Established in 1994 Astec Lifesciences Limited manufactures a wide range of agrochemicals and pharmaceutical intermediates. With over two decades of experience in development and production of selected chemicals the company
Corporate Actions
Date
Type
Details
Company details
Astec Lifesciences Share Price
541.70+0.00 (-1.95%)
-34.66% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Astec Lifesciences Share Price
541.70+0.00 (-1.95%)
-34.66% past 1 Year
News
1 of 20
ResultASTEC26 Oct 2026
Astec Lifesciences reported consolidated Q2 revenue of Rs 72.02 crores, down 2.31% year on year from Rs 73.72 crores. Operating loss widened to Rs 19.79 crores from Rs 6.69 crores a year earlier, indicating significant deterioration in operating margins.
Consolidated net loss widened to Rs 37.40 crores from Rs 24.42 crores year on year, a deterioration of approximately 53.15%. Sequential revenue, EBITDA, and quarter on quarter profit comparisons were not provided. The wider operating and net losses reflect weaker quarterly profitability, while no management guidance, consensus comparison, or market reaction was available in the provided information.
The results indicate a negative earnings development for the company.
Astec reports marginal Q2 revenue decline with net loss improvement
ResultASTEC26 Oct 2026
Astec Lifesciences reported Q2 revenue of Rs 72 crores, down approximately 2.33% year on year from Rs 73.72 crores. Revenue declined 13.81% sequentially. Net loss stood at Rs 37 crores, compared with the prior-year figure implied by the reported 53.17% improvement, while gross profit was negative at Rs 30 crores. EBITDA was not provided. The results indicate subdued top-line performance alongside an improvement in the reported net loss and gross profit metrics. No management guidance, consensus comparison, operating margin detail, or market reaction was provided.
Astec Lifesciences Q1 FY27 results: narrower net loss on weaker revenue
ResultASTEC31 Jul 2026
Astec Lifesciences reported its consolidated Q1 results showing a mixed earnings picture, with a reduction in net loss but a decline in revenue on a year-on-year basis. The company posted a consolidated net loss of Rs 18.70 crores in Q1, compared to a larger loss of Rs 33.00 crores in the same quarter last year, indicating an improvement in bottom-line performance despite remaining in the red. This represents a meaningful year-on-year narrowing of the loss, suggesting some progress in cost management, operational efficiencies or product mix, even though detailed margin data and EBITDA figures are not available in the provided context.
On the top line, Q1 revenue stood at Rs 83.60 crores, down from Rs 91.10 crores in the corresponding period a year ago, reflecting a year-on-year decline in sales. The contraction in revenue points to softer demand, pricing pressure or volume challenges for the company’s products during the quarter. As operating margin and net margin data are not disclosed in the context, a granular margin trend analysis is not possible, but the simultaneous revenue decline and improvement in net loss imply that cost controls or non-operating factors may have partially offset weaker sales.
No street consensus, management commentary, guidance or quarter-on-quarter comparison has been provided, so the performance can only be assessed against the prior-year quarter. The results highlight that while Astec Lifesciences continues to report losses, the trajectory of the net result is improving, which may be relevant for investors tracking the company’s turnaround potential. No information on immediate stock price reaction, index-level impact or broader sector implications is available in the given context, so market impact assessment is limited to the nature of the earnings, which appear to be a routine quarterly update for an individual mid-cap/chemical sector stock rather than a market-moving event.
Astec Lifesciences informs about newspaper publication
Stock NewsASTEC3 Jun 2026
NULL
Astec Lifesciences Q4FY25 Results: Reduced Net Loss, Revenue Growth YoY.
ResultASTEC27 Apr 2026
Astec Lifesciences reported its Q4 consolidated financial results, showing improvement in key metrics compared to the previous year. The company posted a net loss of Rs 7.75 crores, narrower than the Rs 16.10 crores loss in the year-ago quarter. Revenue from operations rose to Rs 159.00 crores, up from Rs 120.00 crores YoY, reflecting a growth of approximately 32.5%.
This performance indicates better top-line expansion despite remaining in loss territory. No details on EBITDA, margins, or QoQ comparisons were provided in the results announcement. Street expectations or management guidance were not mentioned.
Astec Lifesciences reports Profit after tax of Rs -7.78 Crores, in the March 2026 quarter
ResultASTEC27 Apr 2026
NULL
Astec Lifesciences - Quaterly Results
ResultASTEC30 Jan 2026
NULL
Astec Lifesciences Q3 FY25 Results: EBITDA Loss Narrows to Rs 3.8 Crore from Rs 17.4 Crore YoY.
ResultASTEC30 Jan 2026
Astec Lifesciences Limited reported consolidated total income of Rs 95.8 Crore in Q3 FY25, up 85.2% from Rs 51.7 Crore in Q3 FY24. Consolidated EBITDA loss narrowed to Rs 3.8 Crore from Rs 17.4 Crore YoY. Profit Before Tax (PBT) loss was Rs 25.1 Crore versus Rs 32.2 Crore YoY. Net Profit after Tax (PAT) loss stood at Rs 40.4 Crore compared to Rs 24.3 Crore YoY.
For 9M FY25, total income was Rs 266.6 Crore, down 13.4% from Rs 308.0 Crore in 9M FY24. EBITDA loss widened to Rs 66.9 Crore from Rs 15.0 Crore. PBT loss was Rs 125.3 Crore versus Rs 60.8 Crore, and PAT loss was Rs 118.6 Crore from Rs 45.9 Crore.
Segment-wise, Enterprise revenue rose 21.4% YoY to Rs 34.1 Crore, while Contract Manufacturing surged 163.4% to Rs 59.8 Crore. Geographically, Exports grew 68.1% to Rs 69.6 Crore, and Domestic sales increased 158.5% to Rs 24.3 Crore.
Chairman Mr. N B Godrej noted sequential EBITDA improvement from Rs 17.7 Crore loss in Q2 FY25, driven by higher CDMO volumes, offset by lower realizations in Enterprise products. The company anticipates gradual performance enhancement in coming quarters.
For 9M FY25, total income was Rs 266.6 Crore, down 13.4% from Rs 308.0 Crore in 9M FY24. EBITDA loss widened to Rs 66.9 Crore from Rs 15.0 Crore. PBT loss was Rs 125.3 Crore versus Rs 60.8 Crore, and PAT loss was Rs 118.6 Crore from Rs 45.9 Crore.
Segment-wise, Enterprise revenue rose 21.4% YoY to Rs 34.1 Crore, while Contract Manufacturing surged 163.4% to Rs 59.8 Crore. Geographically, Exports grew 68.1% to Rs 69.6 Crore, and Domestic sales increased 158.5% to Rs 24.3 Crore.
Chairman Mr. N B Godrej noted sequential EBITDA improvement from Rs 17.7 Crore loss in Q2 FY25, driven by higher CDMO volumes, offset by lower realizations in Enterprise products. The company anticipates gradual performance enhancement in coming quarters.
Astec Lifesciences Q3 Consolidated Net Loss Narrows to Rs 15.70 Crores, Revenue Up 33% YoY.
ResultASTEC30 Jan 2026
Astec Lifesciences reported Q3 consolidated results with net loss of Rs 15.70 crores versus loss of Rs 40.40 crores YoY. Revenue rose to Rs 125.00 crores from Rs 93.90 crores YoY, reflecting 33.1% growth.
The narrower loss indicates improved financial performance despite remaining in negative territory. No details on EBITDA, margins, or QoQ changes were provided in the results. Street expectations or management guidance not mentioned.
Context from recent quarters shows ongoing challenges, with Q4 prior year revenue at Rs 120.32 crores and net loss Rs 16.09 crores, alongside TTM losses. Stock underperformed peers amid weak profitability.
Astec Lifesciences CFO Mugdha Amol Khare Resigns from Position.
Stock NewsASTEC30 Jan 2026
Mugdha Amol Khare has resigned as the Chief Financial Officer of Astec Lifesciences Limited. The resignation is noted in recent corporate updates amid a series of key management changes at the company.
Previously, Ms. Khare was appointed as CFO effective 2nd August, 2024, by the Board of Directors based on recommendations from the Nomination and Remuneration Committee and Audit Committee. She is a qualified Chartered Accountant (CA) and Company Secretary (CS) with over 15 years of experience in banking, treasury, forex, tax, and audit. Her career began at KPMG (BSR & Co.), followed by roles at NOCIL Limited, where she contributed to business strategies, risk management, and M&A assignments.
This resignation follows a pattern of leadership transitions. Earlier, Mr. K. Suryanarayan resigned as CFO effective 3rd May, 2024, prior to Ms. Khare's appointment. Other changes include resignations of independent directors like Mr. Vijay Kashinath Khot and Dr. Brahma Nand Vyas due to advancing age, and Mr. Anurag Roy as Whole Time Director & CEO effective 25th October, 2024. Such management changes may influence strategic execution, financial oversight, and investor confidence, though specific impacts on earnings or leverage are not detailed in available disclosures.
Astec Lifesciences reports Profit after tax of Rs -15.72 Crores, in the December 2025 quarter
ResultASTEC30 Jan 2026
NULL
Astec Lifesciences - Quaterly Results
ResultASTEC29 Oct 2025
NULL
Astec Lifesciences Q2 FY26 net loss narrows, revenue declines year-on-year.
ResultASTEC29 Oct 2025
Astec Lifesciences reported its consolidated financial results for the quarter ended September 30, 2025. The company recorded a consolidated net loss of Rs 24.42 crores in Q2, compared to a net loss of Rs 38.55 crores in the same quarter last year, indicating a reduction in losses year-on-year.
Consolidated revenue for the quarter stood at Rs 73.72 crores, lower than the Rs 98.54 crores reported in the corresponding quarter of the previous year. The year-on-year decline in revenue was accompanied by a narrowing of net losses, reflecting ongoing operational challenges but some cost containment or business mix improvement.
Results are in line with the recent company performance trends, including board review and audit committee oversight as per SEBI regulations. No information was released regarding EBITDA, margins, or segmental performance in this announcement.
Key tags: Astec Lifesciences, Agrochemicals, Q2 Results, Earnings, NSE.
Consolidated revenue for the quarter stood at Rs 73.72 crores, lower than the Rs 98.54 crores reported in the corresponding quarter of the previous year. The year-on-year decline in revenue was accompanied by a narrowing of net losses, reflecting ongoing operational challenges but some cost containment or business mix improvement.
Results are in line with the recent company performance trends, including board review and audit committee oversight as per SEBI regulations. No information was released regarding EBITDA, margins, or segmental performance in this announcement.
Key tags: Astec Lifesciences, Agrochemicals, Q2 Results, Earnings, NSE.
Astec Lifesciences reports Profit after tax of Rs -24.45 Crores, in the September 2025 quarter
ResultASTEC29 Oct 2025
NULL
Astec LifeSciences informs about disclosure
Stock NewsASTEC1 Aug 2025
NULL
Astec Lifesciences: Reports Revenue Growth Of 68.2% In Enterprise And 85.7% In Cdmo Businesses Year On Year. ??
Stock NewsASTEC28 Jul 2025
Astec Lifesciences: Reports Revenue Growth Of 68.2% In Enterprise And 85.7% In Cdmo Businesses Year On Year. ??
Astec Lifesciences - Quaterly Results
ResultASTEC28 Jul 2025
NULL
Astec Lifesciences - Quaterly Results
ResultASTEC28 Jul 2025
NULL
Astec Lifesciences - Quaterly Results
ResultASTEC28 Jul 2025
NULL
Astec Lifesciences reports Profit after tax of Rs -33.06 Crores, in the June 2025 quarter
ResultASTEC28 Jul 2025
NULL

